Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Overall Survival
87%
Effector T Cells
50%
18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography
50%
Danish Population
50%
PD-L2
50%
Newly Diagnosed
50%
Population-based Cohort Study
50%
Immune Therapy
50%
Treatment Outcome
50%
Treatment Strategy
50%
Prognostic Impact
50%
Interim PET
50%
Specific T Cells
26%
Lymphoma Patients
25%
Positron Emission Tomography-computed Tomography (PET-CT)
25%
R-CHOP
25%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Overall Survival
68%
Positron Emission Tomography-Computed Tomography
50%
Clinician
50%
Cohort Analysis
50%
Fluorodeoxyglucose F 18
50%
Polyethylene Terephthalate
50%
Comorbidity
30%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Immunology and Microbiology
Immunotherapy
50%
T Cell
50%
Epitope
18%
Programmed Death-Ligand 1
18%
